Application and Funding Trends in Fiscal Year 2023

NIGMS continues to support a broad range of scientific topics and investigators within its research portfolio, including support for investigator-initiated research project grants (RPGs) at institutions throughout the country. As part of its commitment to transparency, NIGMS examines and publishes data on annual trends reflected in its RPG portfolio. In this post, we review and describe investigator-level trends associated with competing R01/R01-equivalent RPGs including those in the Institute’s R35 Maximizing Investigators’ Research Award (MIRA) program. NIGMS Investigator-Level Trends Research Grants In order to focus on supporting a broad group of investigators, we monitor two statistics that describe our investigator pool: the number of early stage investigators (ESIs) funded each year and the cumulative investigator rate. Continued support for ESIs is integral to the success of the biomedical research enterprise and is a priority for the Institute. Figure 1 illustrates the number of ESIs who received their first competing NIGMS R01-equivalent grants each year between fiscal year 2014 (FY14) and FY23. In FY23, NIGMS awarded R01-equivalent grants to a total of 313 ESIs: 26 investigators received R01 awards, 272 investigators received R35 (MIRA) awards, 13 investigators received NIH Director’s New Innovator Awards (DP2s), and 2 investigators received U01 awards. Thus, NIGMS continues to maintain robust support for ESIs, 88% of which constituted R35 MIRA awar...
Source: NIGMS Feedback Loop Blog - National Institute of General Medical Sciences - Category: Biomedical Science Authors: Tags: Director’s Messages Funding Trends Funding Outcomes Funding Policies MIRA NIGMS Strategic Plan R01 Source Type: blogs